Literature DB >> 14663480

Apoptotic cues from the extracellular matrix: regulators of angiogenesis.

Dwayne G Stupack1, David A Cheresh.   

Abstract

A variety of factors cooperate to regulate neovessel formation and persistence. Proangiogenic growth factors have remained an area of intense interest due to their capacity to promote endothelial cell (EC) proliferation and to initiate the angiogenic program. These growth factors are associated with increased cell survival, yet paradoxically, angiogenic ECs are more susceptible to apoptosis than quiescent ECs. Survival is regulated by cooperation between growth factor receptors and integrins, which are in turn governed by the composition of the local extracellular matrix (ECM). Integrin-mediated signaling is altered or disrupted by the presence of soluble, rather than matrix-bound ligands, thus providing a means by which ECM remodeling can influence both integrin- and growth factor-mediated events. Ultimately, the collaboration of these factors determines whether ECs survive or die, thereby regulating neovascularization.

Mesh:

Substances:

Year:  2003        PMID: 14663480     DOI: 10.1038/sj.onc.1207110

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Tick saliva is a potent inhibitor of endothelial cell proliferation and angiogenesis.

Authors:  Ivo M B Francischetti; Thomas N Mather; José M C Ribeiro
Journal:  Thromb Haemost       Date:  2005-07       Impact factor: 5.249

2.  Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation.

Authors:  Barbara Garmy-Susini; Hui Jin; Yuhong Zhu; Rou-Jia Sung; Rosa Hwang; Judy Varner
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

3.  Tissue morphogenesis and vascular stability require the Frem2 protein, product of the mouse myelencephalic blebs gene.

Authors:  John R Timmer; Tracy W Mak; Katia Manova; Kathryn V Anderson; Lee Niswander
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-08       Impact factor: 11.205

4.  CTA combined with CT perfusion for assessing the efficacy of anti-angiogenic therapy in rabbit VX2 tumors.

Authors:  Han Wang; Lin-Feng Zheng; Yan Feng; Xue-Qian Xie; Xiao-Ming Yang; Gui-Xiang Zhang
Journal:  Acad Radiol       Date:  2012-03       Impact factor: 3.173

5.  Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2010-11-01       Impact factor: 5.285

Review 6.  Cell death in the cardiovascular system.

Authors:  Murray Clarke; Martin Bennett; Trevor Littlewood
Journal:  Heart       Date:  2006-03-17       Impact factor: 5.994

7.  Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species.

Authors:  Danyu Sun; Keith R McCrae
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

8.  Effect of ANG II on endothelial cell apoptosis and survival and its impact on skeletal muscle angiogenesis after electrical stimulation.

Authors:  Micheline M de Resende; Andrew S Greene
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-04-25       Impact factor: 4.733

9.  Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo.

Authors:  Jennifer M Roth; Abebe Akalu; Anat Zelmanovich; Desiree Policarpio; Bruce Ng; Shannon MacDonald; Silvia Formenti; Leonard Liebes; Peter C Brooks
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

10.  Increased expression of fibronectin and the alpha 5 beta 1 integrin in angiogenic cerebral blood vessels of mice subject to hypobaric hypoxia.

Authors:  Richard Milner; Stephanie Hung; Bernadette Erokwu; Paula Dore-Duffy; Joseph C LaManna; Gregory J del Zoppo
Journal:  Mol Cell Neurosci       Date:  2008-02-13       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.